Novo Holdings A/S - Q4 2022 holdings

$1.6 Billion is the total value of Novo Holdings A/S's 48 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was 19.2% .

 Value Shares↓ Weighting
SYK  STRYKER CORPORATION$194,844,105
+20.7%
796,9410.0%12.16%
+58.1%
ASML  ASML HOLDING N V$123,907,128
+31.6%
226,7700.0%7.74%
+72.3%
STE  STERIS PLC$86,377,112
+11.1%
467,6870.0%5.39%
+45.4%
CRM  SALESFORCE.COM, INC.$76,703,315
-7.8%
578,5000.0%4.79%
+20.7%
CTLT  CATALENT INC$73,495,839
-37.8%
1,632,8780.0%4.59%
-18.5%
BAM  BROOKFIELD ASSET MGMT INCcl a ltd vt sh$71,928,156
-29.9%
2,508,8300.0%4.49%
-8.2%
CORT BuyCORCEPT THERAPEUTICS INC$68,602,468
-19.6%
3,377,768
+1.5%
4.28%
+5.3%
CABO BuyCABLE ONE INC$66,988,162
-1.9%
94,103
+17.6%
4.18%
+28.5%
BSX SellBOSTON SCIENTIFIC CORP$62,607,058
-8.3%
1,353,081
-23.2%
3.91%
+20.1%
EWTX  EDGEWISE THERAPEUTICS INC$54,281,025
-9.1%
6,071,7030.0%3.39%
+19.0%
TSM  TAIWAN SEMICONDUCTOR MFG LTDsponsored ads$52,946,002
+8.6%
710,7800.0%3.31%
+42.3%
AAPL SellAPPLE INC$47,957,683
-24.8%
369,104
-20.0%
2.99%
-1.5%
NewDISC MEDICINE, INC.$46,557,9622,340,772
+100.0%
2.91%
SellARCELLX, INC.$45,974,940
-23.3%
1,484,020
-53.5%
2.87%
+0.5%
BABA  ALIBABA GROUP HLDG LTDsponsored ads$44,117,850
+10.1%
500,8270.0%2.76%
+44.2%
PCVX SellVAXCYTE INC$34,763,750
+75.8%
725,000
-12.0%
2.17%
+130.1%
BMRN BuyBIOMARIN PHARMACEUTICAL INC$32,878,773
+22.2%
317,700
+0.1%
2.05%
+60.0%
MIRM  MIRUM PHARMACEUTICALS INC$32,841,764
-7.2%
1,684,1930.0%2.05%
+21.5%
VECT  VECTIVBIO HLDG AG$28,919,931
+44.3%
3,339,4840.0%1.81%
+89.1%
SGEN BuySEAGEN INC.$26,987,100
+163.0%
210,000
+180.0%
1.68%
+244.6%
ALNY BuyALNYLAM PHARMACEUTICALS INC$26,616,800
+33.0%
112,000
+12.0%
1.66%
+74.2%
FOLD SellAMICUS THERAPEUTICS INC$25,590,939
+16.7%
2,095,900
-0.2%
1.60%
+52.9%
VERV  VERVE THERAPEUTICS INC$17,629,998
-43.7%
911,1110.0%1.10%
-26.2%
INSM BuyINSMED INC$16,783,200
+1.2%
840,000
+9.1%
1.05%
+32.5%
RCKT BuyROCKET PHARMACEUTICALS INC$16,634,500
+64.7%
850,000
+34.3%
1.04%
+115.6%
BPMC BuyBLUEPRINT MEDICINES CORP$16,209,700
-22.3%
370,000
+16.8%
1.01%
+1.7%
INSP BuyINSPIRE MED SYS INC$15,945,012
+47.6%
63,304
+3.9%
1.00%
+93.4%
NARI BuyINARI MED INC$15,305,248
-1.2%
240,800
+12.9%
0.96%
+29.5%
BuyRALLYBIO CORP$15,084,766
+65.2%
2,296,007
+263.9%
0.94%
+116.6%
TMCI BuyTREACE MED CONCEPTS INC$14,651,918
+12.8%
637,317
+8.3%
0.92%
+47.8%
SILK  SILK RD MED INC$14,560,756
+17.4%
275,5110.0%0.91%
+53.8%
NewDICE THERAPEUTICS, INC.$14,508,000465,000
+100.0%
0.91%
BLU NewBELLUS HEALTH INC.$13,958,2501,698,084
+100.0%
0.87%
CRNX BuyCRINETICS PHARMACEUTICALS IN$13,488,143
+8.7%
737,057
+16.7%
0.84%
+42.5%
PHVS BuyPHARVARIS N V$13,357,204
+185.5%
1,187,307
+94.6%
0.83%
+274.0%
LVTX  LAVA THERAPEUTICS NV$11,645,592
-23.4%
3,327,3120.0%0.73%
+0.3%
ABCL  ABCELLERA BIOLOGICS INC$11,415,649
+2.4%
1,126,9150.0%0.71%
+34.3%
KZR BuyKEZAR LIFE SCIENCES INC$8,272,000
+60.6%
1,175,000
+96.4%
0.52%
+109.8%
RPHM  RENEO PHARMACEUTICALS INC$7,992,778
-30.4%
3,430,3770.0%0.50%
-8.9%
 IO BIOTECH INC$7,539,244
-15.1%
3,277,9320.0%0.47%
+11.1%
CYT  CYTEIR THERAPEUTICS INC$6,501,681
-14.1%
3,940,4130.0%0.41%
+12.5%
KNTE  KINNATE BIOPHARMA INC$4,975,813
-49.0%
815,7070.0%0.31%
-33.1%
SPRB  SPRUCE BIOSCIENCES INC$4,952,227
-19.9%
4,514,3360.0%0.31%
+4.7%
LUNG  PULMONX CORP$4,303,979
-49.4%
510,5550.0%0.27%
-33.7%
GRTX  GALERA THERAPEUTICS INC$3,663,941
-14.4%
2,459,0210.0%0.23%
+12.3%
GLTO  GALECTO INC$2,872,460
-39.2%
2,497,7910.0%0.18%
-20.4%
MQ  MARQETA INC$2,697,919
-14.2%
441,5580.0%0.17%
+12.0%
SPRO  SPERO THERAPEUTICS INC$811,200
-13.5%
468,9020.0%0.05%
+13.3%
ALGS ExitALIGOS THERAPEUTICS INC$0-1,950,000
-100.0%
-0.10%
SPNE ExitSEASPINE HLDGS CORP$0-525,867
-100.0%
-0.14%
BOLT ExitBOLT BIOTHERAPEUTICS INC$0-3,703,991
-100.0%
-0.26%
NKTX ExitNKARTA INC$0-823,200
-100.0%
-0.52%
ExitMINERVA SURGICAL INC$0-1,862,877
-100.0%
-0.82%
MIST ExitMILESTONE PHARMACEUTICALS IN$0-2,000,000
-100.0%
-0.88%
VTI ExitVANGUARD INDEX FDStotal stk mkt$0-1,525,550
-100.0%
-23.88%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2023-02-14
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
VANGUARD INDEX FDS41Q3 202264.7%
INOGEN INC34Q2 202268.8%
VANGUARD INTL EQUITY INDEX F29Q4 201637.6%
AMICUS THERAPEUTICS INC22Q3 20234.1%
AKEBIA THERAPEUTICS INC21Q3 20204.8%
VERONA PHARMA PLC21Q2 20221.9%
CORVUS PHARMACEUTICALS INC20Q4 20207.1%
INSPIRE MED SYS INC20Q3 20231.8%
CABLE ONE INC19Q3 20239.7%
FLEXION THERAPEUTICS INC19Q3 20214.7%

View Novo Holdings A/S's complete holdings history.

Latest significant ownerships (13-D/G)
Novo Holdings A/S Q4 2022 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
Cyteir Therapeutics, Inc.August 03, 20231,547,1364.4%
Disc Medicine, Inc.June 28, 20231,090,7724.8%
Galera Therapeutics, Inc.June 28, 20232,100,0004.9%
VectivBio Holding AGSold outMay 26, 202300.0%
LanzaTech Global, Inc.February 17, 202315,814,8458.1%
Bolt Biotherapeutics, Inc.Sold outJanuary 04, 202300.0%
Arcellx, Inc.December 12, 20221,750,0004.0%
MINERVA SURGICAL INCNovember 03, 20221,322,4734.5%
Milestone Pharmaceuticals Inc.October 24, 20221,378,5384.6%
Galecto, Inc.September 30, 20222,497,7919.8%

View Novo Holdings A/S's complete significant-ownership history.

Latest filings
TypeFiled
SC 13D/A2024-03-28
42024-03-25
SC 13D/A2024-03-25
42024-03-20
SC 13D/A2024-03-20
1442024-03-18
42024-03-18
SC 13D/A2024-03-18
1442024-03-14
SC 13D/A2024-03-07

View Novo Holdings A/S's complete filings history.

Compare quarters

Export Novo Holdings A/S's holdings